Obesity Surgery

, Volume 21, Issue 11, pp 1792–1797 | Cite as

The Two Major Epidemics of the Twenty-First Century: Obesity and Cancer

  • Orit Kaidar-Person
  • Gil Bar-Sela
  • Benjamin PersonEmail author


It is a well-known fact that severe obesity is associated with the metabolic syndrome, type 2 diabetes, cardiovascular disease, hypertension, and other diseases. Epidemiological studies have suggested that obesity is also associated with increased risk of several cancer types. The number of people who are suffering from severe obesity is growing, and clinical data suggest that severely obese patients belong to a unique population with regards to risk, efficacy of screening, and cancer treatment. This review will point out the potential mechanism linking obesity and cancer and will discuss several challenges in various treatment modalities of cancer in obese patients.


Obesity Insulin resistance Metabolic syndrome Cancer Surgery Bariatric 


Conflicts of Interest



  1. 1.
    Padidar S, Farquharson AJ, Williams LM, et al. Leptin upregulates pro-inflammatory cytokines in discrete cells within mouse colon. J Cell Physiol. 2011;226(8):2123–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Rahmati-Yamchi M, Zarghami N, Rahbani M, et al. Plasma leptin, hTERT gene expression, and anthropometric measures in obese and non-obese women with breast cancer. Breast Cancer (Auckl). 2011;5:27–35.Google Scholar
  3. 3.
    Key TJ. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids. 2011;76(8):812–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Calle EE, Rodriquez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRefGoogle Scholar
  5. 5.
    Pan SY, DesMeules M. Energy intake, physical activity, energy balance, and cancer: epidemiologic evidence. Methods Mol Biol. 2009;472:191–215.PubMedCrossRefGoogle Scholar
  6. 6.
    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95:1218–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Cleary MP, Grossmann ME. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology. 2009;150:2537–42.PubMedCrossRefGoogle Scholar
  9. 9.
    Kabat GC, Kim M, Chlebowski RT, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:2046–53.PubMedCrossRefGoogle Scholar
  10. 10.
    Seewaldt VL, Goldenberg V, Jones LW, et al. Overweight and obese perimenopausal and postmenopausal women exhibit increased abnormal mammary epithelial cytology. Cancer Epidemiol Biomarkers Prev. 2007;16:613–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Silva TC, Barrett-Connor E, Ramires JA, et al. Obesity, estrone, and coronary artery disease in postmenopausal women. Maturitas. 2008;59:242–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Helzlsouer KJ, Alberg AJ, Bush TL, et al. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev. 1994;18(2):79–85.PubMedGoogle Scholar
  13. 13.
    Rosenberg CR, Pasternack BS, Shore RE, et al. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol. 1994;140(6):518–25.PubMedGoogle Scholar
  14. 14.
    Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer. 1997;76(3):401–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Kabuto M, Akiba S, Stevens RG, et al. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev. 2000;9(6):575–9.PubMedGoogle Scholar
  16. 16.
    Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer. 2004;112(2):312–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2005;97(10):755–65.PubMedCrossRefGoogle Scholar
  18. 18.
    Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv Exp Med Biol. 2008;630:148–65.PubMedCrossRefGoogle Scholar
  19. 19.
    Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002;7:3–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;2:CD007506.PubMedGoogle Scholar
  21. 21.
    Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107:28–36.PubMedCrossRefGoogle Scholar
  22. 22.
    Austin H, Austin Jr JM, Partridge EE, et al. Endoometrial cancer, obesity, and body fat distribution. Cancer Res. 1991;51(2):568–72.PubMedGoogle Scholar
  23. 23.
    Gerhardsson de Verdier M, Hagman U, Steineck G, et al. Diet, body mass and colorectal cancer: a case-referent study in Stockholm. Int J Cancer. 1990;46:832–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Dietz AT, Newcomb PA, Marcus PM, et al. The association of body size and large bowel cancer risk in Wisconsin (United States) women. Cancer Causes Control. 1995;6:30–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Caan BJ, Coates AO, Slattery ML, et al. Body size and the risk of colon cancer in a large case–control study. Int J Obes Relat Metab Disord. 1998;22:178–84.PubMedCrossRefGoogle Scholar
  26. 26.
    Russo A, Franceschi S, La Vecchia C, et al. Body size and colorectal-cancer risk. Int J Cancer. 1998;78:161–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Murphy TK, Calle EE, Rodriguez C, et al. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol. 2000;152:847–54.PubMedCrossRefGoogle Scholar
  28. 28.
    Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut. 2002;51:191–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 2006;98:920–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.PubMedCrossRefGoogle Scholar
  31. 31.
    Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res. 2002;10 Suppl 2:97S–104S.PubMedCrossRefGoogle Scholar
  32. 32.
    Garow D. Metabolic syndrome is a risk factor for colorectal cancer in the United States. American College of Gastroenterology 2008 Annual Scientific Meeting. October 6, 2008.Google Scholar
  33. 33.
    Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556–65.PubMedCrossRefGoogle Scholar
  34. 34.
    Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.PubMedCrossRefGoogle Scholar
  35. 35.
    Saydah SH, Platz EA, Rifai N, et al. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:412–8.PubMedGoogle Scholar
  36. 36.
    Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst. 2004;96:546–53.PubMedCrossRefGoogle Scholar
  37. 37.
    Wei EK, Ma J, Pollak MN, et al. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev. 2006;15:750–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Gunter MJ, Leitzman MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem. 2006;17:145–56.PubMedCrossRefGoogle Scholar
  39. 39.
    Trevisan M, Liu J, Muti P, et al. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev. 2001;10:937–41.PubMedGoogle Scholar
  40. 40.
    Stocks T, Lukanova A, Johansson M, et al. Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond). 2008;32:304–14.CrossRefGoogle Scholar
  41. 41.
    Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.PubMedCrossRefGoogle Scholar
  42. 42.
    Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267–73.PubMedCrossRefGoogle Scholar
  43. 43.
    Madarnas Y, Sawka CA, Franssen E, et al. Are medical oncologists biased in their treatment of the large woman with breast cancer? Breast Cancer Res Treat. 2001;66:123–33.PubMedCrossRefGoogle Scholar
  44. 44.
    Abdah-Bortnyak R, Tsalic M, Haim N. Actual body weight for determining doses of chemotherapy in obese cancer patients: evaluation of treatment tolerability. Med Oncol. 2003;20:363–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Rosner GL, Hargis JB, Hollis DR, et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from Cancer and Leukemia Group B Study 8541. J Clin Oncol. 1996;14:3000–8.PubMedGoogle Scholar
  46. 46.
    Schwartz J, Toste B, Dizon DS. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA) > 2 m2. Gynecol Oncol. 2009;114:53–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Wright JD, Tian C, Mutch DG, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:353–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI > or =27 or cachexia. Cancer Chemother Pharmacol. 2006;57:241–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Jenkins P, Elyan S, Freeman S. Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer. Eur J Cancer. 2007;43:544–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 2008;87:429–30.PubMedCrossRefGoogle Scholar
  51. 51.
    Ludwig MS, McNeese MD, Buchholz TA, et al. The lateral decubitus breast boost: description, rationale, and efficacy. Int J Radiat Oncol Biol Phys. 2010;76:100–3.PubMedCrossRefGoogle Scholar
  52. 52.
    Wong JR, Gao Z, Merrick S, et al. Potential for higher treatment failure in obese patients: correlation of elevated body mass index and increased daily prostate deviations from the radiation beam isocenters in an analysis of 1,465 computed tomographic images. Int J Radiat Oncol Biol Phys. 2009;75:49–55.PubMedCrossRefGoogle Scholar
  53. 53.
    Soran A, Wu WC, Dirican A, et al. Estimating the probability of lymphedema after breast cancer surgery. Am J Clin Oncol. 2011 (in press).Google Scholar
  54. 54.
    Benoist S, Panis Y, Alves A, et al. Impact of obesity on surgical outcomes after colorectal resection. Am J Surg. 2000;179:275–81.PubMedCrossRefGoogle Scholar
  55. 55.
    Healy LA, Ryan AM, Sutton E, et al. Impact of obesity on surgical and oncological outcomes in the management of colorectal cancer. Int J Colorectal Dis. 2010;25:1293–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Grotenhuis BA, Wijnhoven BP, Hötte GJ, et al. Prognostic value of body mass index on short-term and long-term outcome after resection of esophageal cancer. World J Surg. 2010;34:2621–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Tsai S, Choti MA, Assumpcao L, et al. Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: a large single-institution study. J Gastrointest Surg. 2010;14:1143–50.PubMedCrossRefGoogle Scholar
  58. 58.
    Merkow RP, Bilimoria KY, McCarter MD, et al. Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg. 2009;208:53–61.PubMedCrossRefGoogle Scholar
  59. 59.
    Lascano CA, Kaidar-Person O, Szomstein S, et al. Challenges of laparoscopic colectomy in the obese patient: a review. Am J Surg. 2006;192:357–65.PubMedCrossRefGoogle Scholar
  60. 60.
    Meyerhardt JA, Tepper JE, Niedzwiecki D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22:648–57.PubMedCrossRefGoogle Scholar
  61. 61.
    You JF, Tang R, Changchien CR, et al. Effect of body mass index on the outcome of patients with rectal cancer receiving curative anterior resection: disparity between the upper and lower rectum. Ann Surg. 2009;249:783–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Al-Refaie WB, Parsons HM, Henderson WG, et al. Body mass index and major cancer surgery outcomes: lack of association or need for alternative measurements of obesity? Ann Surg Oncol. 2010;17:2264–73.PubMedCrossRefGoogle Scholar
  63. 63.
    Ramsey AM, Martin RC. Body mass index and outcomes from pancreatic resection: a review and meta-analysis. J Gastrointest Surg. 2011 (in press).Google Scholar
  64. 64.
    Kritchevsky D. Nutrition and breast cancer. Cancer. 1990;66:1321–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Rapp K, Klenk J, Ulmer H, et al. Weight change and cancer risk in a cohort of more than 65,000 adults in Austria. Ann Oncol. 2008;19:641–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Van Horn L, Vitolins MZ, Wactawski-Wende J, et al. Low fat dietary pattern and risk of invasive breast cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA. 2006;295:629–42.PubMedCrossRefGoogle Scholar
  67. 67.
    Tinker LF, Bonds DE, Margolis KL, et al. Women’s Health Initiative: low fat dietary pattern and risk of treated diabetes mellitus in postmenopausal women: the Women’s Health Initiative randomized controlled dietary modification trial. Arch Intern Med. 2008;168:1500–11.PubMedCrossRefGoogle Scholar
  68. 68.
    Howard BV, Van Horn L, Hsia J, et al. Low fat dietary pattern and risk of cardiovascular disease: the Women’s Health Initiative Randomised Controlled Dietary Modification Trial. JAMA. 2006;295:655–66.PubMedCrossRefGoogle Scholar
  69. 69.
    Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296:193–201.PubMedCrossRefGoogle Scholar
  70. 70.
    Ashrafian H, Ahmed K, Rowland SP, et al. Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer. 2011;117(9):1788–99.PubMedCrossRefGoogle Scholar
  71. 71.
    Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61.PubMedCrossRefGoogle Scholar
  72. 72.
    Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2011

Authors and Affiliations

  • Orit Kaidar-Person
    • 1
  • Gil Bar-Sela
    • 1
  • Benjamin Person
    • 2
    Email author
  1. 1.Division of Oncology, Rambam Health Care Campus and Rappaport Faculty of MedicineTechnion—Israel Institute of TechnologyHaifaIsrael
  2. 2.Department of General Surgery, Rambam Health Care Campus and Rappaport Faculty of MedicineTechnion—Israel Institute of TechnologyHaifaIsrael

Personalised recommendations